Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.
Metabolic balance and calcium kinetic studies were performed in four patients with Paget's disease before treatment with salmon calcitonin and during the early and late stages of the treatment, which lasted 9 to 19 months, A significant decrease in bone turnover and 24-hour urine hydroxyproline and serum alkaline phosphatase values was observed in all patients. In contrast, the calcium, phosphorus and magnesium balances did not change significantly. In agreement with this, the partial body calcium, measured by in vivo neutron activation analysis, did not change. Intestinal calcium absorption increased initially, but returned to baseline levels 9 to 19 months after the study began. During the initial period there was a small, significant, but transient decrease in tubular reabsorption of phosphorus; this was accompanied by a significant decrease in serum phosphorus values--probably a direct effect of calcitonin rather than evidence of secondary hyperparathyroidism. Administration of salmon calcitonin to patients with Paget's disease decreases bone turnover without affecting calcium and phosphorus balances.
D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D001862:Bone Resorption / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007408:Intestinal Absorption; D008274:Magnesium / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy / Q000378:metabolism*; D010758:Phosphorus / Q000378:metabolism; D013997:Time Factors
D010758:Phosphorus; D002116:Calcitonin; D000469:Alkaline Phosphatase; D008274:Magnesium; D006909:Hydroxyproline; D002118:Calcium